Paul J. Ross
Impact in
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.2%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
Papers in
- Oncology 82
- Colorectal Cancer Treatments and Studies 41
- Pancreatic and Hepatic Oncology Research 24
- Colorectal Cancer Surgical Treatments 8
- Hepatology 38
- Hepatocellular Carcinoma Treatment and Prognosis 35
- Co-authors
- David Cunningham (49 shared papers)Ian Chau (13 shared papers)Andrew Richard Norman (19 shared papers)Nina L. Etkin (7 shared papers)Justin S. Waters (7 shared papers)Mark E. Hill (15 shared papers)Jacqui Oates (5 shared papers)Paul Andrew Clarke (3 shared papers)
- Journals
- Annals of Oncology (22 papers)British Journal of Cancer (19 papers)Journal of Clinical Oncology (13 papers)European Journal of Cancer (10 papers)The Lancet Oncology (8 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Paul J. Ross
188 papers receiving 17.1k citations
Paul J. Ross's Hit Papers
Peers
Comparison fields: 5 of 162
- Hepatology 3.7k
- Oncology 7.4k
- Cancer Research 1.9k
- Pulmonary and Respiratory Medicine 3.5k
- Surgery 4.1k
Countries citing papers authored by Paul J. Ross
This map shows the geographic impact of Paul J. Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul J. Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul J. Ross more than expected).
Fields of papers citing papers by Paul J. Ross
This network shows the impact of papers produced by Paul J. Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul J. Ross. The network helps show where Paul J. Ross may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul J. Ross, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 194 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2016 | 3032 |
| 2 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2017 | 1516 |
| 3 | Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Hit paper breakdown → | 2015 | 943 |
| 4 | Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study Hit paper breakdown → | 2019 | 921 |
| 5 | Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial Hit paper breakdown → | 2021 | 546 |
| 6 | SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2014 | 492 |
| 7 | 2004 | 455 | |
| 8 | 1997 | 419 | |
| 9 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial Hit paper breakdown → | 2017 | 406 |
| 10 | 2002 | 401 | |
| 11 | 2004 | 377 | |
| 12 | 2006 | 363 | |
| 13 | Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial Hit paper breakdown → | 2014 | 327 |
| 14 | 1997 | 297 | |
| 15 | 2017 | 283 | |
| 16 | 2015 | 232 | |
| 17 | 1999 | 222 | |
| 18 | Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial Hit paper breakdown → | 2022 | 218 |
| 19 | 2015 | 213 | |
| 20 | 2004 | 207 |
About Paul J. Ross
Paul J. Ross is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Surgery and Pathology and Forensic Medicine, having authored 194 papers that have together received 17.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (41 papers), Hepatocellular Carcinoma Treatment and Prognosis (35 papers), Pancreatic and Hepatic Oncology Research (24 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (22 papers), Gastric Cancer Management and Outcomes (20 papers), Genetic factors in colorectal cancer (9 papers), Colorectal and Anal Carcinomas (9 papers) and Colorectal Cancer Surgical Treatments (8 papers). The work is most often cited by research in Hepatology (3.7k citations), Oncology (7.4k citations), Cancer Research (1.9k citations), Pulmonary and Respiratory Medicine (3.5k citations) and Surgery (4.1k citations). Paul J. Ross has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include David Cunningham, Ian Chau, Andrew Richard Norman, Nina L. Etkin, Justin S. Waters, Mark E. Hill, Jacqui Oates, Paul Andrew Clarke, Zofia E. Dziewanowska and Finbarr E. Cotter. Their work appears in journals such as Annals of Oncology, British Journal of Cancer, Journal of Clinical Oncology, European Journal of Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.